The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial
- 1 May 2019
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 81 (1) , 44-51
Abstract
Background: The restricted mean survival time (RMST) measures have not been used as primary measure of efficacy in HIV/AIDS clinical trials. In this work, we aim to compare analysis based on the difference in RMST (Δ-RMST) measure and 2 other treatment-effect measures in a recent HIV equivalence trial, and to investigate the performance and characteristics of Δ-RMST–based analysis in a simulation study. Setting and Methods: We reanalyzed a recent HIV equivalence trial (ACTG A5257 trial) with hazard ratio and Δ-RMST, and then compared the results with the original analysis based on risk difference estimated by Kaplan–Meier curves (RDKM). In a simulation study, we investigated the performance and operating characteristics of Δ-RMST–based analysis in the setting of non-proportional hazards (PH) ratio. Results: In the ACTG A5257 trial, analyses based on Δ-RMST globally led to similar conclusions as the published finding based on RDKM. By contrast, analyses based on hazard ratio provided some discordant equivalence conclusions compared both with the initial analyses based on RDKM and the Δ-RMST. Results of simulation study indicate that the violation of the PH assumption has an impact on Δ-RMST–based analysis regarding the probability of declaring equivalence. Conclusions: Although the RMST-based analysis is an alternative measure of efficacy in HIV/AIDS, clinical trials such an analysis can be strongly impacted by departures from the PH assumption.Keywords
This publication has 19 references indexed in Scilit:
- Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trialsJournal of Clinical Epidemiology, 2018
- Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled TrialsJournal of Clinical Oncology, 2016
- Choice of effect measure in HIV randomized trialsAIDS, 2015
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority StudiesAnnals of Internal Medicine, 2015
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisJournal of Clinical Oncology, 2014
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStatistics in Medicine, 2011
- Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1Annals of Internal Medicine, 2011
- The Hazards of Hazard RatiosEpidemiology, 2010
- Choice of effect measure for epidemiological dataJournal of Clinical Epidemiology, 2000